arGEN-X, Shire deal

Shire partnered with arGEN-X to discover and develop mAbs against multiple undisclosed targets to treat rare genetic diseases. arGEN-X will use its SIMPLE Antibody platform to isolate and characterize antibodies against targets selected by Shire. Shire has an option to license worldwide rights to lead candidates. ...